Introduction
============

Diabetes mellitus is a metabolic disorder of multiple etiologies, characterized by chronic hyperglycemia and long-term complications.[@b1-dmso-6-049] The overall prevalence of diabetes mellitus in the global population is approximately 6%, of which 90% is type 2 diabetes. India had 32 million diabetics in 2000, and this number is expected to increase to 80 million by 2030.[@b2-dmso-6-049],[@b3-dmso-6-049] Characteristic symptoms are polydipsia, polyuria, blurring of vision, and weight loss; in its most severe form, symptoms are ketoacidosis, nonketotic hyperosmolar coma, and death. The principle laboratory findings of type 2 diabetes mellitus is hyperglycemia, either fasting blood glucose (FBG) level \> 126 mg/dL or glycosylated hemoglobin (HbA~1c~) \>6.5%.[@b4-dmso-6-049] In patients with type 2 diabetes, previous prospective studies have shown an association between the degree of hyperglycemia and increased risk of microvascular complications, sensory neuropathy, myocardial infarction, stroke, macrovascular mortality, and all-cause mortality.[@b5-dmso-6-049] C -reactive protein (CRP) is a main inflammatory factor that is produced by the liver during acute infection or inflammation, and its concentration in plasma can increase as much as 1000-fold during injury and infection. CRP levels are increased in endothelial dysfunction and atherogenesis, and increased levels have been associated with macrovascular disease and the nonocular microvascular complications of type 2 diabetes.[@b6-dmso-6-049]--[@b8-dmso-6-049] CRP is a predictor of early atherosclerotic damage and is related to high adiposity (mainly abdominal), insulin resistance, and dyslipidemia.[@b9-dmso-6-049] CRP directly impairs nitric oxide production, resulting in endothelial dysfunction. In the Atherosclerosis Risk in Communities (ARIC) study,[@b10-dmso-6-049] there was a positive link found between systemic inflammation and the development of type 2 diabetes mellitus and cardiovascular complications. An increase in adenosine deaminase increased serum (S) and tissue adenosine deaminase (ADA) activity is not well known. It is seen that, with higher ADA activity in insulin-sensitive tissues, glucose uptake into cells is reduced;[@b12-dmso-6-049] thus, if ADA activity is suppressed, insulin sensitivity may be improved and cellular proliferation, inflammation, and T-cell activity (all of which are associated with the pathophysiology of insulin resistance) can be altered. The general consensus is that the main treatment of type 2 diabetes is lifestyle management, like exercise and weight reduction. Pharmacological agents, including sulfonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinide, are also used; however, long-term complications of type 2 diabetes mellitus are unaltered with these agents.[@b13-dmso-6-049] Metformin is currently being used in type 2 diabetes as the first-choice oral agent, along with appropriate diet control and lifestyle advice. Metformin acts primarily by reducing the hepatic glucose output and improving insulin sensitivity in the liver and muscle. Metformin has pleiotropic vascular effects that act on endothelial imbalance, probably increasing nitric oxide bioavailability, decreasing atheroma plaque growth, improving the atherogenic lipid profile, and inhibiting lipid incorporation into vessel walls, thereby inhibiting vascular smooth muscle cell proliferation.[@b14-dmso-6-049] The American Diabetic Association has recommended metformin as a first-line agent for the treatment of type 2 diabetes, as metformin helps in weight loss and lowers fasting plasma insulin concentrations, total and low-density lipoprotein cholesterol, and free fatty acids;[@b15-dmso-6-049] however, long-term complications are not altered with metformin therapy. Previous studies[@b16-dmso-6-049],[@b17-dmso-6-049] have shown mixed results of metformin therapy on CRP, but the studies of nondiabetic patients have reported greater inhibitory effects on CRP than the studies of diabetics. Thus, the effect of metformin therapy on CRP needs to be established in type 2 diabetic patients. The World Health Organization Expert Committee on diabetes has recommended that traditional medicinal herbs can be further investigated for the treatment of diabetes.[@b18-dmso-6-049] The following are the most commonly used medicinal herbs: *Allium sativum* (garlic), Ginseng species, *Momordica charantia* (bitter melon), *Trigonella foenum-graecum* (fenugreek) and *A. cepa* (onion). Garlic has a reputation in particular because of its widespread health use around the world as a dietary as well as therapeutic supplement. Garlic contains a variety of effective compounds, such as allicin, a sulfur-containing compound that exhibits anticoagulant, antithrombotic, antioxidant, hypocholesterolemic, hypoglycemic, and hypotensive activities.[@b19-dmso-6-049],[@b20-dmso-6-049] The probable mechanism underlying garlic's hypoglycemic effects is increased insulin secretion and sensitivity. However, apart from its antihyperglycemic and lipid-lowering properties, garlic has been shown to have ADA-inhibiting activities in cultivated endothelial cells.[@b21-dmso-6-049] Similarly, aged garlic extract has been shown to produce favorable effects on inflammatory markers and coronary atherosclerosis progression in diabetics with cardiovascular risk.[@b22-dmso-6-049] However, to the authors' knowledge, there are no studies reporting the effect of garlic on CRP or other markers of inflammation in subjects treated with garlic; in vitro studies have shown only that high concentrations of garlic can decrease cytokine production in endothelial cells, suggesting anti-inflammatory properties.[@b23-dmso-6-049] Aged garlic extract was shown to increase nitric oxide production and decrease the output of inflammatory cytokines from cultured cells in 15 men with coronary artery disease,[@b24-dmso-6-049] hence the significance of investigating the effects of garlic on the markers of inflammation in addition to other markers is important. This study was planned to evaluate the antihyperglycemic, antihyperlipidemic, and CRP- and ADA-lowering effects of garlic in patients with diabetes mellitus and obesity.

Materials and methods
=====================

This was an open-label, prospective, randomized, comparative study conducted in type 2 diabetes mellitus patients with obesity. The patients visiting the Department of Medicine's outpatient clinic at Sri Guru Ram Das Charitable Hospital of the Sri Guru Ram Das Institute of Medical Sciences And Research, Amritsar, Punjab, India were enrolled in the study. A total of 60 patients of either male or female sex, fulfilling the inclusion and exclusion criteria (described below), were included in the study and were divided randomly into two groups of 30 each. The total duration of the study was 12 weeks. Group 1 was given metformin tablets (the control drug), 500 mg twice a day (BD) or three times a day (TDS) after meals, as per each patient's blood glucose profile and drug tolerance. Group 2 was given garlic, one capsule BD after meals along with metformin (control) tablets, 500 mg BD or TDS after meals, as per each patient's blood glucose profile and drug tolerance. The test drug garlic used was available under the brand name of Lasuna and was a 250 mg capsule manufactured by The Himalaya Drug Company (Bangalore, India). The garlic dose administered in this study was chosen using information from the literature provided by The Himalaya Drug Company.[@b25-dmso-6-049]

Patients were followed up at 2-week intervals and were routinely investigated for FBG and postprandial blood glucose (PPBG), as described by the GOD-POD method (using glucose oxidase enzyme),[@b26-dmso-6-049] at day 0 and at 2, 4, 6, 8, and 12 weeks. Additionally, at the beginning and end of the study, the following parameters were tested: S cholesterol (CH), estimated by cholesterol oxidase-phenol-aminophenazone (CHOD-PAP) method;[@b27-dmso-6-049] triglycerides (TG), using glycerolphosphate oxidase-phenol-aminophenazone (GPO-PAP) end point assay method;[@b28-dmso-6-049] high-density lipoprotein cholesterol (HDL-C), by polyethylene glycol cholesterol oxidase-phenol-aminophenazone (PEG-CHOD-PAP) method;[@b29-dmso-6-049] low-density lipoprotein cholesterol (LDL-C), as described by Bairaktar et al;[@b30-dmso-6-049] S high sensitivity CRP (hs-CRP), as described by Mendall et al;[@b31-dmso-6-049] SADA level, as described by Giusti and Galanti;[@b32-dmso-6-049] HbA~1c~, analyzed by a Nycocard^®^ Reader (Axis-Shield Diagnostics Ltd, Dundee, UK);[@b33-dmso-6-049] and body mass index (BMI).[@b34-dmso-6-049]

The study was conducted in accordance with the principles of good clinical practices and the Declaration of Helsinki. The approval of the Sri Guru Ram Das Institute of Medical Sciences and Research ethics committee was obtained prior to the conduct of study. Written informed consent was obtained from all the patients, and all the risks and benefits were explained to patients in their own language. Patients were advised to undertake diet control and regular exercise as per the protocol designed by the World Health Organization,[@b18-dmso-6-049] and to exclude dietary garlic intake.

Inclusion criteria
------------------

The inclusion criteria were male/female patients with type 2 diabetes, aged 40--65 years, with FBG \> 126 mg/dL, HbA~1c~ \> 6.5%, and BMI \> 25 kg/m[@b2-dmso-6-049].

Exclusion criteria
------------------

The following criteria were used to exclude patients from study: type 1 diabetes; past or present history of ketoacidosis; bleeding disorders; surgery in the preceding 6 weeks or anticipated surgery during the trial period; hypersensitivity to the test drug; any cardiovascular, hepatic, or renal disorder; other ailments, like congestive heart failure, tuberculosis, rheumatoid arthritis, and gout; and pregnancy. Candidates could be receiving long-term insulin therapy or any other antihyperglycemic agent apart from metformin.

Statistics
----------

The data obtained were tabulated as mean ± standard deviation (SD) and analyzed using Student's *t*-test. The level of significance was determined as its *P* value with *P* \> 0.05 taken as not significant, *P* \< 0.05 taken as significant at the 5% significance level, *P* \< 0.01 taken as significant at the 1% significance level, and *P* \< 0.001 was taken as highly significant.

Results
=======

The age of participants varied from 40--75 years. The mean age was 53.8 ± 12.2 and 52.8 ± 11.0 years in groups 1 and 2, respectively, and this difference was statistically nonsignificant (*P* \> 0.05).

In group 1, patients received metformin 500 mg BD/TDS after meals for 12 weeks. The baseline FBG was 160.32 ± 16.73 mg/dL, which declined progressively and reached a nadir of 134.97 ± 10.28 mg/dL, and PPBS was 192.38 ± 10.70 mg/dL, which declined progressively and reached a nadir of 150.90 ± 10.28 mg/dL, at the end of 12 weeks.

In group 2, patients received garlic 250 mg BD along with metformin 500 mg BD/TDS after meals for 12 weeks. The baseline FBG was 157.10 ± 13.54 mg/dL, which declined progressively and reached a nadir of 121.34 ± 6.90 mg/dL, and PPBG was 188.32 ± 16.71 mg/dL, which declined progressively and reached a nadir of 140.90±10.20 mg/dL, at the end of 12 weeks. There was a statistically nonsignificant (*P*\>0.05) difference in FBG and PPBG in both the groups at the start of study; however, the mean fall in FBG and PPBG was highly significant (*P*\<0.001) in both groups, ie, group 1 on metformin and group 2 on garlic plus metformin, at the end of study when compared with start of treatment ([Table 1](#t1-dmso-6-049){ref-type="table"}). When group 2 was compared with group 1, there was a significant reduction (*P*\<0.01) for group 2 in FBG and PPBG after starting of treatment until the end of study ([Table 2](#t2-dmso-6-049){ref-type="table"}).

The results of various parameters in group 1 and group 2 are presented in [Tables 3](#t3-dmso-6-049){ref-type="table"} and [4](#t4-dmso-6-049){ref-type="table"}. These results show that there was a nonsignificant difference (*P*\>0.05) in HbA~1c~, lipid profile (SCH, STG, SHDL-C, SLDL-C), and SADA levels, and BMI, between group 1 and group 2 at the start of study ([Table 5](#t5-dmso-6-049){ref-type="table"}).

The mean HbA~1c~ at the beginning of the study in group 1 was 7.67% ± 0.97%, and at the end of the study this decreased to 7.45% ± 0.77%. Similarly, in group 2, the mean HbA~1c~ level was 7.48% ± 0.59% in the beginning and decreased to 7.05% ± 0.50% at the end of 12 weeks. This mean fall in HbA~1c~ was not significant (*P \>* 0.05) in both groups at the start and end of treatment ([Tables 3](#t3-dmso-6-049){ref-type="table"} and [4](#t4-dmso-6-049){ref-type="table"}). However, at the end of treatment, when group 2 was compared with group 1, a significant (*P* \< 0.05) fall in HbA~1c~ was observed in group 2 ([Table 5](#t5-dmso-6-049){ref-type="table"}).

For group 1, the values of various parameters of the lipid profile are presented in [Table 3](#t3-dmso-6-049){ref-type="table"}. The total S CH was 249.53 ± 20.44 mg/dL at the start of study and 242.97 ± 20.83 mg/dL at the end of 12 weeks. STG at the start of study was 190.87 ± 50.47 mg/dL and at the end of 12 weeks was 184.80 ± 48.07 mg/dL. SLDL-C at the start of study was 186.70 ± 26.35 mg/dL and at the end of 12 weeks was 181.60 ± 25.36 mg/dL, and SHDL-C at the start of study was 41.90 ± 7.65 mg/dL and at the end of 12 weeks was 43.93 ± 7.32 mg/dL. There was significant fall (*P* \< 0.05) in S total CH, STG, and SLDL-C, with a significant increase (*P* \< 0.05) in SHDL-C, at the end of treatment in group 1. Similarly in group 2, the lipid profile was as follow: S total CH at the start of study was 254.07 ± 16.03 mg/dL and at the end of 12 weeks was 238.50 ± 19.49 mg/dL; STG at the start of study was 182.60 ± 6.44 mg/dL and at the end of 12 weeks was 170.47 ± 17.10 mg/dL; SLDL-C at the start of study was 188.33 ± 36.46 mg/dL and at the end of 12 weeks was 178.77 ± 34.39 mg/dL, and SHDL-C at the start of study was 42.50 ± 8.96 mg/dL and at the end of 12 weeks was 46.97 ± 9.14 mg/dL. There was significant fall (*P* \< 0.01) in S total CH, STG, and SLDL-C, and a significant increase (*P* \< 0.01) in SHDL-C, at the end of treatment in group 2 ([Table 4](#t4-dmso-6-049){ref-type="table"}). However, when group 2 was compared with group 1 at the end of treatment, it was observed that there was significant fall (*P* \< 0.05) in S total CH, STG, and SLDL-C, and a significant increase (*P* \< 0.01) in SHDL-C in group 2 as compared with group 1 ([Table 5](#t5-dmso-6-049){ref-type="table"}).

The S hs-CRP level in group 1 at the start of treatment was 1.29 ± 1.79 mg/dL and at the end was 1.28 ± 0.09 mg/dL; there was no significant difference (*P* \> 0.05) in S hs-CRP level in group 1 at the end of study when compared with the start of study ([Table 3](#t3-dmso-6-049){ref-type="table"}). Similarly, the SADA level in group 2 at the start of treatment was 1.30 ± 0.71 mg/dL and at the end was 1.25 ± 0.17 mg/dL; there was significant fall (*P* \< 0.05) in SADA level at the end of study when compared with the start of study in group 2 ([Table 4](#t4-dmso-6-049){ref-type="table"}). When levels of SADA in group 2 were compared with those in group 1, there was a nonsignificant difference (*P \>* 0.01) in S hs-CRP at the start of treatment but a significant fall (*P* \< 0.05) in S hs-CRP levels in group 2 at the end of study ([Table 5](#t5-dmso-6-049){ref-type="table"}).

The SADA level in group 1 at the start of treatment was 43.23 ± 16.14 mg/dL and at the end of treatment was 41.48 ± 12.26 mg/dL; there was a nonsignificant fall (*P* \> 0.05) in SADA level at the end of study in group 1, when compared with the start of study ([Table 3](#t3-dmso-6-049){ref-type="table"}). In group 2, SADA level at the start of treatment was 44.62 ± 18.34 mg/dL and at the end was 36.18 ± 16.06 mg/dL; there was a significant fall (*P* \< 0.01) in SADA level at the end of study in group 2 when compared with the start of study ([Table 4](#t4-dmso-6-049){ref-type="table"}). When level of SADA in group 2 was compared to group 1, there was no significant difference (*P*\>0.05) at the start of treatment but a significant fall (*P*\<0.01) in SADA level was seen in group 2 at the end of study ([Table 5](#t5-dmso-6-049){ref-type="table"}).

Discussion
==========

The present study monitored the effects of garlic in comparison with the standard antidiabetic agent, metformin, on glycemic profile, lipid profile, S hs-CRP and SADA levels, and BMI, in patients with type 2 diabetes mellitus and obesity.

Glycemic profile
----------------

It is well established in observational studies that the risk of microvascular and macrovascular complications is related to hyperglycemia, as measured by FBG, PPBG, and HbA~1c~.[@b34-dmso-6-049],[@b35-dmso-6-049] Thus, the reduction of hyperglycemia in type 2 diabetic patient is of utmost importance. In our study, it was observed that with treatment of metformin alone and with metformin plus garlic, there was significant reduction (*P*\<0.01) in FBG and PPBG ([Table 1](#t1-dmso-6-049){ref-type="table"}). However, this reduction was significantly higher (*P*\<0.01) in patients taking garlic along with metformin as compared with metformin alone ([Table 2](#t2-dmso-6-049){ref-type="table"}). Similarly, there was a nonsignificant (*P*\>0.05) reduction in HbA~1c~ in both the groups, but this reduction was higher (*P*\<0.05) in patients taking garlic along with metformin when compared with metformin alone.

Stumvoll et al[@b36-dmso-6-049] conducted a study of metformin in ten patients that showed a highly significant decrease (*P*\<0.001) in FBG and HbA~1c~ at the end of study. Similarly, DeFronzo and Goodman[@b37-dmso-6-049] showed reduction in the glycemic profile with metformin, in multicenter patient trials. These results were in conformity to the present study where a significant decrease (*P*\<0.001) in FBG and PPBG was observed with metformin and with garlic along with metformin. When group 2 was compared with group 1, it was observed that there was significant fall (*P*\<0.01) in FBG and PPBG in patients taking garlic along with metformin when compared with metformin alone ([Table 2](#t2-dmso-6-049){ref-type="table"}). Ashraf et al,[@b38-dmso-6-049] in a 24-week, single blind, placebo-controlled study of 210 type 2 diabetes mellitus patients taking garlic treatment, showed a significant decrease (*P\<*0.005) in FBG as well as HbA~1c~. Sobenin et al,[@b39-dmso-6-049] in the 4-week double-blind, placebo-controlled study of 60 type 2 diabetic patients, observed lowering of FBG, S fructosamine, and STG levels, with a timed-release garlic preparation given along with oral sulfonylurea derivatives. Similarly, in our study, it was observed that garlic supplemented with metformin showed a greater decrease in FBG, PPBG, and HbA~1c~ levels than did metformin alone.

Lipid profile and BMI
---------------------

Obesity is a major recognized risk factor for type 2 diabetes, with its rapidly increasing prevalence resulting in a "diabesity" epidemic. Reductions in weight, TG, and LDL-C, and increase in HDL-C have been recorded in various clinical studies of patients on metformin.[@b40-dmso-6-049] The findings of the present study conclude that there was a significant decrease in S total CH, STG, and SLDL-C, and a significant increase in S HDL-C ([Tables 3](#t3-dmso-6-049){ref-type="table"} and [4](#t4-dmso-6-049){ref-type="table"}) with metformin alone and with garlic along with metformin; however, the reductions in S total CH, STG, and SLDL-C and increase in SHDL-C was greater with metformin plus garlic (*P*\<0.01) ([Table 5](#t5-dmso-6-049){ref-type="table"}). The reduction in BMI was not significant (*P*\>0.05) in both the groups at the start and at the end of treatment.

Wulfellé et al[@b41-dmso-6-049] conducted a randomized, controlled study for 6 weeks of patients with type 2 diabetes mellitus on metformin and showed a significant decrease (*P*\<0.05) in SCH, STG, and SLDL-C levels. However, in contrast to the above findings, the decrease in the same parameters was highly significant (*P*\<0.01) in the present study. In another study conducted by Wu et al[@b42-dmso-6-049] of 12 patients with type 2 diabetes mellitus on metformin therapy showed a significant decrease (*P*\<0.05) in FBG and STG levels and a significant increase in SHDL-C levels. This was in conformity to the present study, where a significant decrease in FBG (*P*\<0.001) and TG (*P*\<0.05) levels and significant increase (*P*\<05) in SHDL-C levels were observed. Ashraf et al,[@b38-dmso-6-049] in a 12-week, randomized, single-blind, placebo-controlled study of type 2 diabetes mellitus patients on garlic, showed a highly significant decrease (*P*\<0.01) in total CH and S LDL-C levels and a significant increase (*P*\<0.05) in S HDL-C level. These results are comparable with the present study, where a highly significant decrease (*P*\<0.01) in S total CH, STG and SLDL-C levels and a highly significant increase (*P*\<0.01) in S HDL-C levels were observed in patients taking garlic along with metformin. In another study conducted by Santen et al,[@b43-dmso-6-049] the lipid-lowering effect of garlic was studied in 40 diabetics with hyperlipidemia, and it showed a highly significant decrease (*P*\<0.01) in S TG levels and a significant decrease (*P*\<0.05) in total CH levels. This difference was comparable with the present study, where the decrease in SCH and TG levels was significant (*P*\<0.05) in patients taking garlic along with metformin as compared with metformin alone.

Effect on S hs-CRP
------------------

In patients taking only metformin, there was a nonsignificant reduction (*P*\>0.05) in S hs-CRP levels ([Table 3](#t3-dmso-6-049){ref-type="table"}), whereas there was a significant reduction (*P*\<0.05) in S hs-CRP levels, in type 2 diabetic patients taking metformin supplemented with garlic ([Table 4](#t4-dmso-6-049){ref-type="table"}), at the end of study. When S hs-CRP level was compared between group 1 and group 2, it was observed that there was a significant fall (*P*\<0.05) in S hs-CRP levels in group 2 ([Table 5](#t5-dmso-6-049){ref-type="table"}). Thus, it can be interpreted from present study that metformin treatment does not cause statistically significant lowering of CRP levels, but metformin plus garlic treatment significantly decreases the CRP levels. However, long-term studies are required to elucidate the findings of the present study.

CRP reduction with metformin has been widely evaluated in many other studies. Caballero et al,[@b16-dmso-6-049] in their study on the differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance, observed that metformin improved the plasma levels of some markers of endothelial activation and coagulation in subjects with impaired glucose tolerance, whereas it had no effect on markers of inflammation. Pradhan et al,[@b44-dmso-6-049] in a study of 500 adults with type 2 diabetes, concluded that treatment with metformin, compared with placebo, did not reduce inflammatory biomarker levels, despite improvement of glucose control. Similarly, Lima et al[@b14-dmso-6-049] conducted a double-blind, placebo-controlled, prospective, 24-week study in 32 nondiabetic first-degree relatives of patients with type 2 diabetes mellitus who were given extended-release metformin, 500 mg once daily. Researchers concluded that there was no change in S hs-CRP level.

SADA activity
-------------

Previous studies[@b11-dmso-6-049],[@b19-dmso-6-049] have revealed that in type 2 diabetic patients, with increase in HbA~1c~ level, there is an increase in SADA level. In line with previous work done by other researchers, the SADA level in the present study of type 2 diabetes mellitus patients was significantly higher in both the groups ([Tables 3](#t3-dmso-6-049){ref-type="table"} and [4](#t4-dmso-6-049){ref-type="table"}). However, the fall in SADA levels was not significant (*P*\>0.05) in patients given metformin only when compared with patients taking metformin plus garlic (*P*\<0.01) ([Table 5](#t5-dmso-6-049){ref-type="table"}). Similarly, Koch et al[@b45-dmso-6-049] reported an inhibition of the enzyme ADA with garlic in in-vitro study. This is in conformity to our findings, where a significant (*P*\<0.01) decrease in S SADA level was seen in patients taking garlic along with metformin, signifying an ADA-lowering effect of garlic.

Conclusion
==========

At the end of 12 weeks, it was observed that both metformin and garlic reduced FBG, PPBG, and HbA~1c~ significantly, but the percentage of change in FBG and PPBG was more substantial with metformin supplemented with garlic than with metformin alone, whereas the difference in mean percentage of change in HbA~1c~ was not significant. Similarly, the beneficial effect of metformin supplemented with garlic on lipid profile parameters, such as the fall in total CH, TG, LDL-C and increase in HDL-C, were greater with metformin supplemented with garlic than with metformin alone. Similarly, the fall in CRP and SADA levels were seen more notably with metformin supplemented with garlic than with metformin alone. These results lead us to conclude that there is an adjuvant role of garlic, along with other antidiabetic agents, in the treatment and prevention of long-term complications of type 2 diabetes mellitus. However, more clinical trials using garlic in combination with different antidiabetic agents are warranted, to further explore the benefits of garlic in type 2 diabetics.
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###### 

Fasting and postprandial blood glucose levels in both groups at different time intervals

  Group     Day 0            Week 2                                                        Week 4                                                       Week 6                                                       Week 8                                                       Week 12
  --------- ---------------- ------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------ --------------------------------------------------------------
  Group 1                                                                                                                                                                                                                                                                         
    FBG     160.32 ± 16.73   154.7 ± 15.47[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}    149.9 ± 14.15[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   146.6 ± 13.57[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   140.8 ± 11.91[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   134.9 ± 10.28[\*\*\*](#tfn2-dmso-6-049){ref-type="table-fn"}
    PPBG    192.38 ± 10.70   173.7 ± 15.40[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}    160.9 ± 14.18[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   156.6 ± 13.53[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   154.8 ± 11.91[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   150.9 ± 10.28[\*\*\*](#tfn2-dmso-6-049){ref-type="table-fn"}
  Group 2                                                                                                                                                                                                                                                                         
    FBG     157.10 ± 13.54   141.0 ± 13.36[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}    129.8 ± 12.24[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   130.6 ± 11.04[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   125.9 ± 9.22[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}    121.34 ± 6.90[\*\*\*](#tfn2-dmso-6-049){ref-type="table-fn"}
    PPBG    188.32 ± 16.71   164.74 ± 15.43[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   151.9 ± 14.10[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   145.6 ± 13.54[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   144.8 ± 11.98[\*\*](#tfn1-dmso-6-049){ref-type="table-fn"}   140.9 ± 10.20[\*\*\*](#tfn2-dmso-6-049){ref-type="table-fn"}

**Notes**: Values are expressed as mean ± standard deviation.

*P* \< 0.01 (significant at 1% significance level);

*P* \< 0.001 (highly significant). **Abbreviations**: FBG, fasting blood glucose; PPBG, postprandial blood glucose.

###### 

Comparison of fasting and postprandial blood glucose levels in both groups at different time intervals

  Duration   FBG (mean±SD)     PPBG (mean±SD)                                                                   
  ---------- ----------------- -------------------------------------------------------------- ----------------- --------------------------------------------------------------
  Day 0      160.32 ± 16.73    157.10 ± 13.54[NS](#tfn3-dmso-6-049){ref-type="table-fn"}      192.38 ± 10.70    188.32 ± 16.71[NS](#tfn3-dmso-6-049){ref-type="table-fn"}
  Week 2       154.7 ± 15.47     141.0 ± 13.36[\*](#tfn4-dmso-6-049){ref-type="table-fn"}       173.7 ± 15.40   164.74 ± 15.43\*
  Week 4       149.9 ± 14.15     129.8 ± 12.24[\*\*](#tfn5-dmso-6-049){ref-type="table-fn"}     160.9 ± 14.18     151.9 ± 14.10[\*\*](#tfn5-dmso-6-049){ref-type="table-fn"}
  Week 6       146.6 ± 13.57     130.6 ± 11.04[\*\*](#tfn5-dmso-6-049){ref-type="table-fn"}     156.6 ± 13.53     145.6 ± 13.54[\*\*](#tfn5-dmso-6-049){ref-type="table-fn"}
  Week 8       140.8 ± 11.91     125.9 ± 9.22[\*\*](#tfn5-dmso-6-049){ref-type="table-fn"}      154.8 ± 11.91     144.8 ± 11.98[\*\*](#tfn5-dmso-6-049){ref-type="table-fn"}
  Week 12      134.9 ± 10.28   121.34 ± 6.90[\*\*](#tfn5-dmso-6-049){ref-type="table-fn"}       150.9 ± 10.2      140.9 ± 10.20[\*\*](#tfn5-dmso-6-049){ref-type="table-fn"}

**Notes**:

*P*\>0.05 (not significant);

*P*\<0.05 (significant at 5% significance level);

*P*\<0.01 (significant at 1% significance level).

**Abbreviations**: FBG, fasting blood glucose; PPBG, postprandial blood glucose; SD, standard deviation.

###### 

Results of various study parameters in group 1

  Parameters              Day 0            Week 12                                                     Change
  ----------------------- ---------------- ----------------------------------------------------------- --------
  HbA~1c~(%)              7.67 ± 0.97      7.45 ± 0.77[NS](#tfn6-dmso-6-049){ref-type="table-fn"}      -2%
  BMI (kg/m^2^)           27.23 ± 2.77     26.86 ± 12.69[NS](#tfn6-dmso-6-049){ref-type="table-fn"}    -1%
  S hs-CRP (mg/dL)        1.29 ± 1.79      1.28 ± 0.09[NS](#tfn6-dmso-6-049){ref-type="table-fn"}      \-
  S ADA (U/L)             43.23 ± 16.14    41.48 ± 12.26[NS](#tfn6-dmso-6-049){ref-type="table-fn"}    -4%
  Lipid profile (mg/dL)                                                                                
    S total cholesterol   249.53 ± 20.44   242.97 ± 20.83[\*](#tfn7-dmso-6-049){ref-type="table-fn"}   -2%
    S triglyceride        190.87 ± 50.47   184.80 ± 48.07[\*](#tfn7-dmso-6-049){ref-type="table-fn"}   -3%
    S LDL-C               186.70 ± 26.35   181.60 ± 25.36[\*](#tfn7-dmso-6-049){ref-type="table-fn"}   -2%
    S HDL-C               41.90 ± 7.65     43.93 ± 7.32[\*](#tfn7-dmso-6-049){ref-type="table-fn"}     +4%

**Notes**: Values are expressed as mean ± standard deviation.

*P*\>0.05 (not significant);

*P*\<0.05 (significant at 5% significance level).

**Abbreviations**: ADA, adenosine deaminase; BMI, body mass index; HbA~1c~, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; S, serum.

###### 

Results of various study parameters in group 2

  Parameter               Day 0            Week 12                                                         Change
  ----------------------- ---------------- --------------------------------------------------------------- --------
  HbA~1c~(%)              7.40 ± 0.59      7.05 ± 0.50[NS](#tfn8-dmso-6-049){ref-type="table-fn"}          -4%
  BMI (kg/m^2^)           27.72 ± 1.74     25.97 ± 10.70[NS](#tfn8-dmso-6-049){ref-type="table-fn"}        -6%
  S hs-CRP(mg/dL)         1.30 ± 0.71      1.25 ± 0.17[\*](#tfn9-dmso-6-049){ref-type="table-fn"}          -3%
  S ADA(U/L)              45.62 ± 18.34    36\. 18 ± 16.06[\*\*](#tfn10-dmso-6-049){ref-type="table-fn"}   -20%
  Lipid profile (mg/dL)                                                                                    
    S total cholesterol   254.07 ± 16.03   238.50 ± 19.49[\*](#tfn9-dmso-6-049){ref-type="table-fn"}       -6%
    S triglyceride        182.60 ± 6.44    170.47 ± 7.17[\*](#tfn9-dmso-6-049){ref-type="table-fn"}        -6%
    S LDL-C               188.33 ± 36.46   178.77 ± 34.39[\*](#tfn9-dmso-6-049){ref-type="table-fn"}       -5%
    S HDL-C               42.50 ± 8.96     46.97 ± 9.14[\*\*](#tfn10-dmso-6-049){ref-type="table-fn"}      +10%

**Notes**: Values are expressed as mean ± standard deviation.

*P*\>0.05 (not significant);

*P*\<0.05 (significant at 5% significance level);

*P*\<0.01 (significant at 1% significance level).

**Abbreviations**: ADA, adenosine deaminase; BMI, body mass index; HbA~1c~, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; S, serum.

###### 

Comparison of various parameters in both groups

  Parameter               Day 0            Week 12                                                                       
  ----------------------- ---------------- ------------------------------------------------------------ ---------------- -------------------------------------------------------------
  HbA~1c~ (%)             7.67 ± 0.90      7.40 ± 0.5[NS](#tfn11-dmso-6-049){ref-type="table-fn"}       7.45 ± 0.70      7.05 ± 0.5[\*](#tfn12-dmso-6-049){ref-type="table-fn"}
  BMI (kg/m^2^)           27.23 ± 2.77     27.72 ± 1.74[NS](#tfn11-dmso-6-049){ref-type="table-fn"}     26.86 ± 12.69    25.97 ± 10.70[NS](#tfn11-dmso-6-049){ref-type="table-fn"}
  S hs-CRP (mg/dL)        1.29 ± 1.79      1.30 ± 0.71[NS](#tfn11-dmso-6-049){ref-type="table-fn"}      1.28 ± 0.09      1.25 ± 0.17[\*](#tfn12-dmso-6-049){ref-type="table-fn"}
  SADA (U/L)              43.23 ± 16.14    44.62 ± 18.34[NS](#tfn11-dmso-6-049){ref-type="table-fn"}    42.40 ± 12.26    36.18 ± 16.06[\*\*](#tfn13-dmso-6-049){ref-type="table-fn"}
  Lipid profile (mg/dL)                                                                                                  
    S total cholesterol   249.53 ± 20.44   254.07 ± 16.03[NS](#tfn11-dmso-6-049){ref-type="table-fn"}   242.97 ± 20.83   231.50 ± 19.49[\*](#tfn12-dmso-6-049){ref-type="table-fn"}
    S triglyceride        190.87 ± 50.47   185.60 ± 6.44[NS](#tfn11-dmso-6-049){ref-type="table-fn"}    184.80 ± 48.07   170.47 ± 17.10[\*](#tfn12-dmso-6-049){ref-type="table-fn"}
    S LDL-C               186.70 ± 26.35   188.33 ± 36.46[NS](#tfn11-dmso-6-049){ref-type="table-fn"}   181.60 ± 25.36   170.77 ± 34.39[\*](#tfn12-dmso-6-049){ref-type="table-fn"}
    S HDL-C               41.90 ± 7.65     42.50 ± 8.96[NS](#tfn11-dmso-6-049){ref-type="table-fn"}     43.93 ± 7.32     47.97 ± 9.14[\*\*](#tfn13-dmso-6-049){ref-type="table-fn"}

**Notes**: Values are expressed as mean ± standard deviation.

*P\>*0.05 (not significant);

*P\<*0.05 (significant at 5% significance level);

*P\<*0.01 (significant at 1% significance level).

**Abbreviations**: ADA, adenosine deaminase; BMI, body mass index; HbA~1c~, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; S, serum.
